Breaking Barriers: Combining Cell Line Development Innovation With Improved Process Development Workflows To Streamline Path To FIH

This webinar will explore how KBI Biopharma’s SUREtechnology Platform™, powered by Selexis®, accelerates the development of complex biologics from early stages to first-in-human (FIH) trials, focusing on both speed and quality. Key topics include:

• Optimized Cell Line Development: Discover how the SUREtechnology Platform™ integrates to create high-performing, stable cell lines tailored for biologics production, accelerating the entire process.

• Transposase and Versatility: Learn about the platform’s modular workflows and advanced transposase technology, which enhance gene insertion efficiency and improve clone performance consistency, reducing cell line development bottlenecks.

• Streamlined Path to Toxicology: A step-by-step look at how the platform shortens the timeline to preclinical toxicology studies, ensuring rapid transitions from cell line development to tox studies.

• Speed to FIH: See how KBI Biopharma’s expertise accelerates the path to first-in-human studies, helping customers achieve critical clinical milestones quickly and confidently.